Epinephrine: Difference between revisions

(Replace static Indications section with dynamic SMW query table pulling dosing from all disease pages)
(Switch SMW query from broadtable to table format for better layout with TOC)
 
(One intermediate revision by the same user not shown)
Line 102: Line 102:
  |?Has Route=Route
  |?Has Route=Route
  |?Has Population=Population
  |?Has Population=Population
  |format=broadtable
  |format=table
  |headers=plain
  |headers=plain
  |link=subject
  |mainlabel=-
  |sort=Has Indication
  |sort=Has Indication
  |limit=50
  |limit=50

Latest revision as of 21:55, 20 March 2026

See critical care quick reference for drug doses by weight.

General

  • Type: Vasopressors
  • Dosage Forms:
  • Concentration
    • Amount of solution in mL used to dilute 1,000mg of epinephrine
    • eg 1:10,000 = 1,000mg/10,000mL = 0.1mg/mL
  • Common Trade Names: Adrenaline, EpiPen (IM autoinjector)

Adult Dosing

Anaphylaxis

0.3-0.5mg of 1:1,000 IM

  • Consider glucagon 1-5mg IV if patient on beta-blockers and not responding to epi

Anaphylactic shock

0.1mg of 1:10,000 slow IV during 5 min, can start infusion of 1-4 mcg/min

Cardiac Arrest

1mg of 1:10,000 IVP (10cc's total or 1 "amp")

Quick Epi Drip

  • Take your code-cart epinephrine (it does not matter if It is 1:1,000 or 1:10,000) and inject 1mg into a liter bag of NS. Final concentration is 1mcg/ml. Run at 1cc/min and titrate to effect.

Pressor drip

  • 0.1-1 mcg/kg/min

Pediatric Dosing

See critical care quick reference for drug doses by weight.

Pulseless Arrest[1]

  • 0.01 mg/kg (1:10,000 solution) IV/IO q3-5 min
  • Max: 1mg/dose

Anaphylaxis

  • 0.01 mg/kg (1:1,000 solution) SC/IM x 1
    • Max: 0.3 mg/dose in pre-pubertal patients; 0.5 mg/dose in teenage patients
    • May repeat dose q5-15 min x 2

Severe Asthma

  • 0.01 mg/kg (1:1,000 solution) SC/IM x 1
    • Max: 0.3 mg/dose in pre-pubertal patients; 0.5 mg/dose in teenage patients
    • May repeat dose q5-15 min x 2

Pressor drip

  • 0.1-1 mcg/kg/min

Special Populations

Contraindications

  • Allergy to class/drug

Adverse Reactions

Pharmacology

  • Onset of action: 1-2 minutes (IV), 8-10 minutes (IM)
  • Half-life: < 5 minutes (IV)[2], 45 minutes (IM)
  • Metabolism: Hepatic
  • Excretion: Renal
  • Mechanism of action: potent α and β agonist that increases cardiac output and peripheral vascular resistance

Mechanism of Action

Primary Receptor

  • β1
  • α1
  • β2

Relative Effects

  • ↑↑↑HR
  • ↑↑↑SV
  • ↑↑↑SVR
  • Bronchodilation (β2)

Dose-dependent effects

  • 1-10 mcg/min - increase HR and SV ("inotropic" epinephrine)
  • 10-20 mcg/min - increase SVR

Notes

  • ↑lactate occurs primarily from ↑glycolysis/glycogenolysis within skeletal muscles not tissue hypoperfusion
  • Use with caution in patients with CAD
    • However clinical trials have not demonstrated worsened outcomes

Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Acute asthma exacerbation0.01 mg/kg (1:1000) SC or IM q20min x3 (max 0.5 mg)Severe/life-threatening asthmaSC/IMAdult
Angioedema0.3 mg IMAllergic/anaphylactic angioedemaIMAdult
Croup0.5 mL/kg of 1:1000 nebulized (max 5 mL); or 0.05 mL/kg racemic epi 2.25% (max 0.5 mL)Moderate-severe croup with stridor at restNebulizedPediatric
Newborn resuscitation0.01-0.03mg/kg (0.1-0.3mL/kg of 1:10,000) IV/IO q3-5minPersistent bradycardia despite ventilation and compressionsIV/IOPediatric
Pulseless arrest1 mg q3-5 minPulseless arrestIV/IOAdult
Pulseless arrest1 mg q3-5 minPulseless arrest (asystole/PEA)IV/IOAdult
Sepsis (main)1-20 mcg/min3rd line vasopressorIV dripAdult
Vasopressors1-10 mcg/min (0.01-0.1 mcg/kg/min), max 0.5 mcg/kg/min2nd/3rd line vasopressorIV dripAdult
Vasopressors0.01-0.5mcg/kg/minVasopressor/inotrope; consider in refractory shockIVAdult

See Also

References

  1. PALS
  2. Dalal R, Grujic D. Epinephrine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482160/

http://www.atsjournals.org/doi/abs/10.1164/rccm.201006-0972CI?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#readcube-epdf